Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to 140.69%.

  • Iovance Biotherapeutics' EBITDA Margin rose 114200.0% to 140.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 166.31%, marking a year-over-year increase of 3069100.0%. This contributed to the annual value of 240.92% for FY2024, which is 384940700.0% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its EBITDA Margin stood at 140.69% for Q3 2025, which was up 114200.0% from 189.78% recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' EBITDA Margin ranged from a high of 117.48% in Q4 2024 and a low of 46254.62% during Q2 2023
  • Moreover, its 3-year median value for EBITDA Margin was 286.7% (2024), whereas its average is 11428.64%.
  • As far as peak fluctuations go, Iovance Biotherapeutics' EBITDA Margin soared by 459269900bps in 2024, and later surged by 114200bps in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' EBITDA Margin (Quarter) stood at 25156.85% in 2023, then soared by 100bps to 117.48% in 2024, then fell by -20bps to 140.69% in 2025.
  • Its EBITDA Margin was 140.69% in Q3 2025, compared to 189.78% in Q2 2025 and 245.76% in Q1 2025.